Uditha Bulugahapitiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Uditha Bulugahapitiya has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chandrika Jayakanthi Subasinghe
Colombo North Teaching Hospital, Ragama
2 shared publications - Knut Erik Berge
Oslo University Hospital, Ullevaal, Oslo
2 shared publications - Nirmala Dushyanthi Sirisena
University of Colombo
2 shared publications - Trond Paul Leren
Unit for Cardiac and Cardiovascular Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
2 shared publications - Vajira Harshadeva Weerabaddana Dissanayake
Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
2 shared publications - A. G. H. Sugathapala
Colombo South Teaching Hospital, Kalubowila
1 shared publication
Latest Publications
- Open Access
- 30 May 2024
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 15 (1) , 33-36
A Rare Manifestation of a Rare Disease: Ectopic Cushing’s Syndrome Secondary to Olfactory Neuroblastoma
Introduction: Olfactory Neuroblastoma (ONB) is a rare malignant Neuroendocrine tumour. It is rarely reported to cause Ectopic Cushing’s Syndrome (ECS). Here, we report a case of ECS secondary to ONB.Case Description: A 40-year-old lady presented with right sided focal seizures complicated with status epilepticus. She was diagnosed with Diabetes Mellitus with severe hyperglycaemia three weeks prior to this admission and started on insulin therapy. Investigations revealed severe hypokalaemia. MRI brain showed no focal lesions but there was mucosal thickening in the paranasal sinuses. Other electrolytes and screening for infections were normal.She didn’t have obvious clinical features of Cushing syndrome except generalized monomorphic acne, but further assessment confirmed the diagnosis of severe ACTH dependant Cushing syndrome. MRI pituitary was normal. CECT Chest, Abdomen and Pelvis showed only enlarged adrenal glands. PET/CT revealed FDG avid nasal polyp. Histology of nasal polyp revealed olfactory neuroblastoma. Staging imaging with MRI brain with sinuses and orbits confirmed stage C tumour with extension into ethmoid sinuses and part of the brain. She underwent endoscopic resection of the tumour and radiotherapy.Conclusion: In a case of ECS, we should look beyond the thoracoabdominal region including Sino nasal cavity.
- 30 May 2024
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 15 (1) , 33-36
Open AccessA Rare Manifestation of a Rare Disease: Ectopic Cushing’s Syndrome Secondary to Olfactory Neuroblastoma
Introduction: Olfactory Neuroblastoma (ONB) is a rare malignant Neuroendocrine tumour. It is rarely reported to cause Ectopic Cushing’s Syndrome (ECS). Here, we report a case of ECS secondary to ONB.Case Description: A 40-year-old lady presented with right sided focal seizures complicated with status epilepticus. She was diagnosed with Diabetes Mellitus with severe hyperglycaemia three weeks prior to this admission and started on insulin therapy. Investigations revealed severe hypokalaemia. MRI brain showed no focal lesions but there was mucosal thickening in the paranasal sinuses. Other electrolytes and screening for infections were normal.She didn’t have obvious clinical features of Cushing syndrome except generalized monomorphic acne, but further assessment confirmed the diagnosis of severe ACTH dependant Cushing syndrome. MRI pituitary was normal. CECT Chest, Abdomen and Pelvis showed only enlarged adrenal glands. PET/CT revealed FDG avid nasal polyp. Histology of nasal polyp revealed olfactory neuroblastoma. Staging imaging with MRI brain with sinuses and orbits confirmed stage C tumour with extension into ethmoid sinuses and part of the brain. She underwent endoscopic resection of the tumour and radiotherapy.Conclusion: In a case of ECS, we should look beyond the thoracoabdominal region including Sino nasal cavity.
- Open Access
- 28 June 2022
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 12 (1) , 56
Primary Hyperparathyroidism: An under-diagnosed endocrine disorder in Sri Lanka
- 28 June 2022
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 12 (1) , 56
Open AccessPrimary Hyperparathyroidism: An under-diagnosed endocrine disorder in Sri Lanka
- Open Access
- 2 June 2022
- Published by MDPI AG in Endocrines
- Vol. 3 (2) , 317-328
Review on the Transgender Literature: Where Are We Now and a Step beyond the Current Practice?
The transgender concept is described as a clinically significant distress due to the incongruity between the experienced gender and assigned gender. A transgender person carries a gender identity that is different from their assigned sex at birth. Transgender people may be binary: male to female (transgender women) or female to male (transgender men) or genderqueer (non-binary, fluid or variable gender expression). The binary concept has been described in transgender population, where the term transwomen is used to describe people assigned male at birth (AMAB) who are recognized as females during gender transition; with the term transmen where they are assigned female at birth (AFAB) and are then recognized as males in gender transition. According to the DSM-5 classification, gender dysphoria is described when a transgender person develops clinically relevant bio-psychosocial suffering. Currently, the transgender population has gained massive public awareness through social media and gained a considerable level of attention globally. Several studies on transgender populations from different parts of the world have shown real discrimination and stigma towards transgender people, which sometimes acts as a barrier to the provision of the required care for them. Lack of access to the required information, legal issues, lack of solutions to fertility problems, financial constraints, and psychological and emotional obstacles, together with risk of sexually transmitted infections, including human immunodeficiency virus (HIV), all make the life of a transgender person more complicated. Testosterone therapy is a hormone-based therapy for transgender men that provides a body image tallying with the favored gender identification, whereas estrogen and androgen-suppressing agents are used in transgender females to produce changes compatible with their required gender identity. Gender affirmation surgery is a broad term, under which the genital reconstruction is described as a major component. Psychological conditions such as depression, substance abuse, suicidal deaths, and sexually transmitted infections, particularly among males having sex with males, are reported at a significantly higher rate among transgender populations. Cardiovascular morbidity is higher among this population, and continuous medical surveillance is warranted. Medical care provision to transgender populations should be handled with great care, while attending to the unmet needs of this population, as this care should extend beyond routine hormonal therapy and gender reassignment surgery.
- 2 June 2022
- Published by MDPI AG in Endocrines
- Vol. 3 (2) , 317-328
Open AccessReview on the Transgender Literature: Where Are We Now and a Step beyond the Current Practice?
The transgender concept is described as a clinically significant distress due to the incongruity between the experienced gender and assigned gender. A transgender person carries a gender identity that is different from their assigned sex at birth. Transgender people may be binary: male to female (transgender women) or female to male (transgender men) or genderqueer (non-binary, fluid or variable gender expression). The binary concept has been described in transgender population, where the term transwomen is used to describe people assigned male at birth (AMAB) who are recognized as females during gender transition; with the term transmen where they are assigned female at birth (AFAB) and are then recognized as males in gender transition. According to the DSM-5 classification, gender dysphoria is described when a transgender person develops clinically relevant bio-psychosocial suffering. Currently, the transgender population has gained massive public awareness through social media and gained a considerable level of attention globally. Several studies on transgender populations from different parts of the world have shown real discrimination and stigma towards transgender people, which sometimes acts as a barrier to the provision of the required care for them. Lack of access to the required information, legal issues, lack of solutions to fertility problems, financial constraints, and psychological and emotional obstacles, together with risk of sexually transmitted infections, including human immunodeficiency virus (HIV), all make the life of a transgender person more complicated. Testosterone therapy is a hormone-based therapy for transgender men that provides a body image tallying with the favored gender identification, whereas estrogen and androgen-suppressing agents are used in transgender females to produce changes compatible with their required gender identity. Gender affirmation surgery is a broad term, under which the genital reconstruction is described as a major component. Psychological conditions such as depression, substance abuse, suicidal deaths, and sexually transmitted infections, particularly among males having sex with males, are reported at a significantly higher rate among transgender populations. Cardiovascular morbidity is higher among this population, and continuous medical surveillance is warranted. Medical care provision to transgender populations should be handled with great care, while attending to the unmet needs of this population, as this care should extend beyond routine hormonal therapy and gender reassignment surgery.
- Open Access
- 1 June 2020
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 10 (1) , 26
Hypokalaemic Paralysis - A double trouble from concurrent Thyrotoxicosis and Gitelman syndrome: A report of two cases
- 1 June 2020
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 10 (1) , 26
Open AccessHypokalaemic Paralysis - A double trouble from concurrent Thyrotoxicosis and Gitelman syndrome: A report of two cases
- Open Access
- 26 April 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 140
Novel mutation in the SLC12A3 gene in a Sri Lankan family with Gitelman syndrome & coexistent diabetes: a case report
Gitelman syndrome (GS) is a rare autosomal recessively inherited salt-wasting tubulopathy associated with mutations in the SLC12A3 gene, which encodes for NaCl cotransporter (NCC) in the kidney. In this report, we describe two siblings from a Sri Lankan non-consanguineous family presenting with hypokalaemia associated with renal potassium wasting, hypomagnesemia, hypocalciuria and hypereninemic hyperaldosteronism with normal blood pressure. Genetic testing showed that both were homozygotes for a novel missense mutation in exon 10 of the SLC12A3 gene [NM_000339.2, c.1276A > T; p.N426Y], which has not previously been reported in the literature in association with GS. Their mother was a heterozygous carrier for the same mutation. The father was not alive at the time of testing. This novel mutation extends the spectrum of known SLC12A3 gene mutations and further supports the allelic heterogeneity of GS. Interestingly both siblings had young onset Diabetes with strong family history. These findings have implications in providing appropriate genetic counseling to the family with regard to the risk associated with inbreeding, the detection of carrier/presymptomatic relatives. It further expands the known spectrum of genotypic and phenotypic characteristics of Gitelman syndrome.
- 26 April 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 140
Open AccessNovel mutation in the SLC12A3 gene in a Sri Lankan family with Gitelman syndrome & coexistent diabetes: a case report
Gitelman syndrome (GS) is a rare autosomal recessively inherited salt-wasting tubulopathy associated with mutations in the SLC12A3 gene, which encodes for NaCl cotransporter (NCC) in the kidney. In this report, we describe two siblings from a Sri Lankan non-consanguineous family presenting with hypokalaemia associated with renal potassium wasting, hypomagnesemia, hypocalciuria and hypereninemic hyperaldosteronism with normal blood pressure. Genetic testing showed that both were homozygotes for a novel missense mutation in exon 10 of the SLC12A3 gene [NM_000339.2, c.1276A > T; p.N426Y], which has not previously been reported in the literature in association with GS. Their mother was a heterozygous carrier for the same mutation. The father was not alive at the time of testing. This novel mutation extends the spectrum of known SLC12A3 gene mutations and further supports the allelic heterogeneity of GS. Interestingly both siblings had young onset Diabetes with strong family history. These findings have implications in providing appropriate genetic counseling to the family with regard to the risk associated with inbreeding, the detection of carrier/presymptomatic relatives. It further expands the known spectrum of genotypic and phenotypic characteristics of Gitelman syndrome.